EP3877444 - MULTI-PEG LIPID COMPOUNDS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 15.03.2024 Database last updated on 24.08.2024 | |
Former | Request for examination was made Status updated on 13.08.2021 | ||
Former | The international publication has been made Status updated on 16.05.2020 | ||
Former | unknown Status updated on 17.02.2020 | Most recent event Tooltip | 16.07.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Translate Bio, Inc. 200 West Street Waltham, MA 02451 / US | [2022/25] |
Former [2021/37] | For all designated states Translate Bio, Inc. 29 Hartwell Avenue Lexington, MA 02421 / US | Inventor(s) | 01 /
KARVE, Shrirang C/o Translate Bio, Inc. 29 Hartwell Avenue Lexington, MA 02421 / US | 02 /
ZHANG, Yi C/o Translate Bio, Inc. 29 Hartwell Avenue Lexington, MA 02421 / US | 03 /
DeROSA, Frank C/o Translate Bio, Inc. 29 Hartwell Avenue Lexington, MA 02421 / US | 04 /
HEARTLEIN, Michael C/o Translate Bio, Inc. 29 Hartwell Avenue Lexington, MA 02421 / US | [2021/37] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2021/37] | Application number, filing date | 19848836.3 | 07.11.2019 | [2021/37] | WO2019US60335 | Priority number, date | US201862758148P | 09.11.2018 Original published format: US 201862758148 P | [2021/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020097376 | Date: | 14.05.2020 | Language: | EN | [2020/20] | Type: | A1 Application with search report | No.: | EP3877444 | Date: | 15.09.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2020 takes the place of the publication of the European patent application. | [2021/37] | Search report(s) | International search report - published on: | EP | 14.05.2020 | Classification | IPC: | C08G65/331, A61K38/00, A61K47/50, A61K47/54, C08G65/332, C08G65/333 | [2021/37] | CPC: |
C08G65/33303 (EP);
A61K9/1272 (EP,US);
A61K31/7105 (EP);
A61K45/06 (US);
A61K47/60 (EP);
A61K47/6911 (EP);
A61K9/0019 (EP);
A61K9/127 (EP);
A61P11/00 (EP);
C08G65/3311 (EP);
C08G65/332 (EP);
C08G65/3322 (US);
C08G65/33306 (US);
C08G65/3356 (US);
C12N15/87 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/37] | Title | German: | MULTI-PEG LIPIDVERBINDUNGEN | [2021/37] | English: | MULTI-PEG LIPID COMPOUNDS | [2021/37] | French: | COMPOSÉS LIPIDIQUES COMPORTANT PLUSIEURS GROUPES PEG | [2021/37] | Entry into regional phase | 12.05.2021 | National basic fee paid | 12.05.2021 | Designation fee(s) paid | 12.05.2021 | Examination fee paid | Examination procedure | 12.05.2021 | Amendment by applicant (claims and/or description) | 12.05.2021 | Examination requested [2021/37] | 12.05.2021 | Date on which the examining division has become responsible | 14.03.2024 | Despatch of a communication from the examining division (Time limit: M04) | 15.07.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 08.11.2021 | Renewal fee patent year 03 | 15.09.2022 | Renewal fee patent year 04 | 13.09.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XAI]US2012202890 (WU NIAN [US]) [X] 1-3,21 * paragraph [[0089]] * * claim 15 * * tables 3-5 * * claims 19-20 * [A] 55-65[I] 4-20,22-54; | [X]US2015157721 (WU NIAN [US]) [X] 1-3 * table 14 * * claims 1-18 * | by applicant | US4310505 | US4373071 | US4401796 | US4415732 | US4458066 | US4500707 | US4668777 | US4897355 | US4973679 | US5047524 | US5132418 | US5153319 | US5171678 | US5262530 | US5334761 | US5700642 | US5744335 | US5885613 | WO2005121348 | WO2010042877 | WO2010053572 | WO2010144740 | US8093367 | US8304529 | WO2012170889 | WO2013063468 | WO2013149140 | WO2015095340 | WO2015184256 | WO2015199952 | WO2016004202 | US2016031928 | WO2016118725 | WO2016118724 | WO2016205691 | WO2017004143 | WO2017049245 | WO2017075531 | WO2017117528 | WO2017173054 | - S. M. BERGE et al., "pharmaceutically acceptable salts", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - JEMIELITY, J. et al., "Novel 'anti-reverse' cap analogs with superior translational properties", RNA, (20030000), vol. 9, doi:10.1261/rna.5430403, pages 1108 - 1122, XP002466761 DOI: http://dx.doi.org/10.1261/rna.5430403 | - JEMIELITY, J. et al., RNA, (20030000), vol. 9, pages 1108 - 1122 | - GRUDZIEN, E. et al., RNA, (20040000), vol. 10, pages 1479 - 1487 | - GRUDZIEN-NOGALSKA, E. et al., RNA, (20070000), vol. 13, pages 1745 - 1755 | - YOKOE et al., Nature Biotechnology, (19960000), vol. 14, pages 1252 - 1256 | - LASIC, Trends Biotechnol., (19980000), vol. 16, pages 307 - 321 | - J. MCCLELLANM. C. KING, Cell, (20100000), vol. 141, pages 210 - 217 | - WHITEHEAD et al., Nature Communications, (20140000), vol. 5, page 4277 | - FEIGNER et al., Proc. Nat'l Acad. Sci., (19870000), vol. 84, page 7413 | - BEHR et al., Proc. Nat.'I Acad. Sci., (19890000), vol. 86, page 6982 | - SEMPLE et al., Nature Biotech., (20100000), vol. 28, pages 172 - 176 | - HEYES, J. et al., J Controlled Release, (20050000), vol. 107, pages 276 - 287 | - MORRISSEY, DV. et al., Nat. Biotechnol., (20050000), vol. 23, no. 8, pages 1003 - 1007 | - GAO et al., Biochem. Biophys. Res. Comm., (19910000), vol. 179, page 280 | - WOLF et al., BioTechniques, (19970000), vol. 23, page 139 | - KLIBANOV et al., FEBS Letters, (19900000), vol. 268, no. 1, pages 235 - 237 | - LUBKE et al., "Proteomics of the Lysosome", Biochim Biophys Acta, (20090000), vol. 1793, doi:10.1016/j.bbamcr.2008.09.018, pages 625 - 635, XP026073291 DOI: http://dx.doi.org/10.1016/j.bbamcr.2008.09.018 |